Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Synlogic Links Up With AbbVie For IBD Microbiome Therapies

This article was originally published in Scrip

Executive Summary

Synlogic Inc., focused on the intersection of synthetic biology and microbiome therapeutics, signed its first partnership Feb. 10, agreeing to a multi-year collaboration with AbbVie Inc. to develop what it calls "synthetic biotic" therapies for Crohn's disease and ulcerative colitis.


Related Content

Synlogic Moves Synthetic Biotics To The Clinic For Rare Metabolic Disease
Deal Watch: Takeda Signs Broad Cancer Collaboration With Nektar
Finance Watch: Two More US Biopharma IPOs And Two New European VC Funds
Sanger Institute Spin-Out Microbiotica To Evaluate Bacterial Mixes
Synthetic Biology And The Computerization Of Drug Development





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts